BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 18032839)

  • 1. Osteonecrosis in patients with human immunodeficiency virus type 1 infection in Taiwan.
    Ho YC; Shih TT; Lin YH; Hsiao CF; Chen MY; Hsieh SM; Sheng WH; Sun HY; Hung CC; Chang SC
    Jpn J Infect Dis; 2007 Nov; 60(6):382-6. PubMed ID: 18032839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteonecrosis complicating highly active antiretroviral therapy in patients infected with human immunodeficiency virus.
    Monier P; McKown K; Bronze MS
    Clin Infect Dis; 2000 Dec; 31(6):1488-92. PubMed ID: 11096017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved survival of persons with human immunodeficiency virus type 1 infection in the era of highly active antiretroviral therapy in Taiwan.
    Hung CC; Hsiao CF; Chen MY; Hsieh SM; Chang SY; Sheng WH; Sun HY; Chang SC
    Jpn J Infect Dis; 2006 Aug; 59(4):222-8. PubMed ID: 16936339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fatal lactic acidosis associated with highly active antiretroviral therapy in patients with advanced human immunodeficiency virus infection in Taiwan.
    Sheng WH; Hsieh SM; Lee SC; Chen MY; Wang JT; Hung CC; Chang SC
    Int J STD AIDS; 2004 Apr; 15(4):249-53. PubMed ID: 15075019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osteonecrosis in six HIV-infected patients receiving highly active antiretroviral therapy.
    Molia AC; Strady C; Rouger C; Beguinot IM; Berger JL; Trenque TC
    Ann Pharmacother; 2004 Dec; 38(12):2050-4. PubMed ID: 15507502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
    Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
    Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors for osteonecrosis in HIV-infected patients: impact of treatment with combination antiretroviral therapy.
    Mary-Krause M; Billaud E; Poizot-Martin I; Simon A; Dhiver C; Dupont C; Salmon D; Roudiere L; Costagliola D;
    AIDS; 2006 Aug; 20(12):1627-35. PubMed ID: 16868444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of Toxoplasma gondii infection and incidence of toxoplasma encephalitis in non-haemophiliac HIV-1-infected adults in Taiwan.
    Hung CC; Chen MY; Hsieh SM; Hsiao CF; Sheng WH; Chang SC
    Int J STD AIDS; 2005 Apr; 16(4):302-6. PubMed ID: 15899084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
    Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
    AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Symptomatic bone disorders in HIV-infected patients: incidence in the Aquitaine cohort (1999-2002).
    Martin K; Lawson-Ayayi S; Miremont-Salamé G; Blaizeau MJ; Balestre E; Lacoste D; Ragnaud JM; Malvy D; Dupon M; Mercié P; Schaeverbeke T; Haramburu F; Dabis F;
    HIV Med; 2004 Nov; 5(6):421-6. PubMed ID: 15544694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients.
    Soria A; Porten K; Fampou-Toundji JC; Galli L; Mougnutou R; Buard V; Kfutwah A; Vessière A; Rousset D; Teck R; Calmy A; Ciaffi L; Lazzarin A; Gianotti N
    Antivir Ther; 2009; 14(3):339-47. PubMed ID: 19474468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study.
    Khanna N; Elzi L; Mueller NJ; Garzoni C; Cavassini M; Fux CA; Vernazza P; Bernasconi E; Battegay M; Hirsch HH;
    Clin Infect Dis; 2009 May; 48(10):1459-66. PubMed ID: 19348592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
    Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.
    Patel K; Hernán MA; Williams PL; Seeger JD; McIntosh K; Van Dyke RB; Seage GR;
    Clin Infect Dis; 2008 Feb; 46(4):507-15. PubMed ID: 18199042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of recurrent nontyphoid Salmonella bacteremia in HIV-infected patients in the era of highly active antiretroviral therapy and an increasing trend of fluoroquinolone resistance.
    Hung CC; Hung MN; Hsueh PR; Chang SY; Chen MY; Hsieh SM; Sheng WH; Sun HY; Huang YT; Lo YC; Hsiao CF; Chang SC
    Clin Infect Dis; 2007 Sep; 45(5):e60-7. PubMed ID: 17682981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postnatal HIV-1 transmission after cessation of infant extended antiretroviral prophylaxis and effect of maternal highly active antiretroviral therapy.
    Taha TE; Kumwenda J; Cole SR; Hoover DR; Kafulafula G; Fowler MG; Thigpen MC; Li Q; Kumwenda NI; Mofenson L
    J Infect Dis; 2009 Nov; 200(10):1490-7. PubMed ID: 19832114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-1 genotype after interruption of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and virological response after resumption of the same regimen.
    Sungkanuparph S; Kiertiburanakul S; Apisarnthanarak A; Malathum K; Sathapatayavongs B
    Int J STD AIDS; 2007 Dec; 18(12):832-4. PubMed ID: 18073016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of repeated cycles of structured therapy interruption on the rate of recovery of CD4+ T cells after highly active antiretroviral therapy resumption.
    León A; Martinez E; Milinkovic A; Mora B; Mallolas J; Blanco JL; Larrousse M; Laguno M; Gallart T; Plana M; Gatell JM; Garcia F
    J Antimicrob Chemother; 2009 Jan; 63(1):184-8. PubMed ID: 19001447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone disorders in human immunodeficiency virus infection.
    Glesby MJ
    Clin Infect Dis; 2003; 37 Suppl 2():S91-5. PubMed ID: 12942380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.